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Abstract
Background: Several symptom-relieving interventions have been shown to be efficacious among osteoarthritis
(OA) patients with knee effusion; however, not every symptomatic knee OA patient has clinical effusion. Results
may be over-generalized since it is unclear if effused knees represent a unique pathological condition or subset
compared to knees without effusion. The primary purpose of this study was to determine if biochemical
differences existed between OA knees with and without effusion.
Methods: The present cross-sectional study consisted of 22 volunteers (11 with knee effusion, 11 without knee
effusion) with confirmed late-stage radiographic knee OA (Kellgren-Lawrence score ≥ 3). Synovial fluid samples
were collected and analyzed using a custom multiplex enzyme-linked immunosorbent assay to determine eight
specific biomarker concentrations (e.g., catabolic, anabolic).
Results: Matrix metalloproteinase (MMP)-3, tissue inhibitor of MMPs (TIMP)-1, TIMP-2, and interleukin-10 were
significantly higher in the knees with effusion than in the knees without effusion.
Conclusions: The biochemical differences that existed between knees with and without effusion provide support
that OA subsets may exist, characterized by distinct biochemical characteristics and clinical findings (e.g., effusion).
Background
Osteoarthritis (OA) is a heterogeneous disease disabling
more than 27 million United States adults [1]. Patients
with knee OA commonly present with pain, stiffness, effu-
sion, and functional impairment. Symptoms may be modu-
lated by effusion as patients with knee effusion are often
more symptomatic [2-4] and have greater improvement in
pain and function to symptom-modifying interventions
than patients without knee effusion [5]. Based on magnetic
resonance imaging findings, patients with knee effusion
comprise 30 to 76% of patients with knee OA [6,7]. OA
knees with effusion, particularly those with active effusion
processes, may be a discreet subset of patients with unique
clinical characteristics (e.g., effusion, increased symptoms,
increased therapeutic response) and at greater risk for car-
tilage loss over time [8,9]. Although knees with effusion
respond well to pain-relieving treatments, there is potential
for over generalization of results since it is unclear if OA
knees with and without effusion represent unique bio-
chemical conditions. Biochemical analyses may distinguish
unique OA phenotypes [10] which may be clinically dis-
tinct (e.g., different symptom severity) and respond
uniquely to interventions.
The primary purpose of this study was to determine if
biochemical differences existed between OA knees with
and without clinical effusion. The hypothesis of this study
was that OA knees with effusion would have elevated
inflammatory mediators when compared to OA knees
without effusion. Highly sensitive clinical and biochemical
data may help identify discreet subsets of patients that can
be targeted for improved diagnosis, interventions, and gen-
otyping of OA, [5,11] ultimately, improving the overall
care of knee OA patients.
Methods
Study Design and Participants
This cross-sectional study was approved by the Institu-
tional Review Board, and informed consent was obtained
from each patient prior to participation in the study.
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from November 2009 to August 2010 at an orthopedic
practice with a board-certified orthopedic surgeon spe-
cializing in hip and knee arthroplasty. Twenty-two
volunteers (11 knees with effusion, 11 knees without
effusion) with late-stage knee OA (Kellgren-Lawrence
score ≥ 3) [12] participated in the study. Prior standard
weight-bearing anterior-posterior radiographs with
knees in full extension were used to assess OA severity
utilizing the Kellgren-Lawrence score [13]. New radio-
graphs were ordered and graded by the orthopedic sur-
geon if the participant’s radiographs were taken more
than 12 months prior to study inclusion. An investiga-
tor-generated medical history form was used to screen
for exclusion criteria, as well as to record medication
and supplement use, injury history, effusion history, and
sport participation history. Patients were excluded from
the study if they indicted acute knee trauma (i.e., injury,
surgery) within three months of study participation,
intraarticular corticosteroid knee injection within thirty
days prior to study participation, or documented history
of other forms of arthritis (e.g., rheumatoid, gout,
pseudogout).
Effusion Status
Effusion status was based on a clinical examination by the
orthopedic surgeon, utilizing observation, palpation, a
modified patellar ballottement test [14], and whether or
not aspiration of the knee was successful. Knee with effu-
sion was defined as a knee that felt and looked swollen,
had a positive patellar ballottement test, and did not
require saline injection for synovial fluid aspiration. A
knee without effusion was defined as a knee that did not
feel or look swollen, had a negative patellar ballottement
test, and required a saline injection to successfully aspirate
synovial fluid.
Sample Acquisition, Storage, and Analysis
Upon completion of all study-related documentation and
assessment, the participant’s involved OA knee joint was
aspirated in accordance with the orthopaedic surgeon’s
standard procedures. The aspiration consisted of vigor-
ously cleaning the needle insertion site with isopropyl
alcohol and using an 18 to 21 gauge 3.81 cm disposable
n e e d l ew i t ha2 0o r6 0c m
3 syringe to aspirate the joint
through the lateral suprapatellar pouch. If the knee did
not have an effusion, the physician injected 5 to 15 cm
3
of sterile saline into the knee to “washout” the synovial
fluid prior to aspiration. A successful saline-assisted
aspiration was defined by the recovery of fluid with the
color of healthy synovial fluid. For all knees, the physician
aspirated as much synovial fluid as could be drawn,
which was then visually inspected to ensure that it was a
healthy color. Healthy synovial fluid was successfully
obtained from all 22 volunteers, and no samples were
excluded based on signs of blood, turbidity, or sepsis.
Synovial Fluid Analysis
A portion (1.0 to 2.0 cc) of the aspirated synovial fluid
was placed in a cryovial and stored in a -80°C freezer
until all of the samples were collected. Once all synovial
fluid samples were collected, they were shipped to
Aushon Biosystems Laboratory (Billerica, MA) without
centrifuging for analysis. Knee synovial fluid biomarker
concentrations were analyzed with a custom human
SearchLight Proteome Multiplex Protein Array. The cus-
tom array is a quantitative multiplexed sandwich
enzyme-linked immunosorbent assay, containing eight
different antibodies. The study focused on eight specific
biomarkers, which were categorized as follows: (1) pro-
tective or anabolic-associated biomarkers (i.e., interleukin
[IL]-10, IL-13, tissue inhibitor of matrix metalloprotei-
nase [TIMP]-1, TIMP-2, and osteoprotegerin [OPG]), (2)
anabolic biomarker associated with cartilage ossification
and neovascularization (i.e., vascular endothelial growth
factor [VEGF]), (3) catabolic-associated biomarker (i.e.,
matrix metalloproteinase [MMP]-3), and (4) pro-inflam-
matory associated biomarker (i.e., IL-1b). All of these
biomarkers have been reported to be altered in the syno-
vial fluid of OA joints in comparison to healthy, non-OA
knees [10,15]; however, no distinction was made between
OA knees with and without effusion in these previous
studies.
Concentrations of each biomarker were analyzed in
duplicate and then averaged. In order to take into account
the injection of saline into the non-effused knees, cytokine
data were normalized to the total protein content of each
sample, which was determined by a bicinchoninic acid
assay (ThermoScientific, Chicago, IL). Normalization of
the data allowed for comparison between the two groups,
as knees without effusion required saline-assisted aspira-
tions that diluted an unknown amount of synovial fluid,
which was not the case for the knees with effusion.
Validity of the SearchLight proteome assays has been
established through the spiked recovery rates for the 8
biomarkers analyzed, which ranged from 62 to 134%
(mean recovery ranges from 76 to 114%). Sensitivity and
intra-assay coefficient of variation measures for the eight
biomarkers analyzed were: IL- 10 (sensitivity = 0.8 pg/
mL, intra-assay coefficient of variation = 6.7%), IL-13
(sensitivity = 0.4 pg/mL, intra-assay coefficient of varia-
tion = 8.1%), TIMP-1 (sensitivity = 9.8 pg/mL, intra-assay
coefficient of variation = 13.8%), TIMP-2 (sensitivity =
9.8 pg/mL, intra-assay coefficient of variation = 8.4%),
OPG (sensitivity = 0.4 pg/mL, intra-assay coefficient
of variation = 8.9%), VEGF (sensitivity = 9.8 pg/mL,
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(sensitivity = 19.6 pg/mL, intra-assay coefficient of varia-
tion = 8.9%), and IL-1b (sensitivity = 0.4 pg/mL, intra-
assay coefficient of variation = 8.2%).
Statistical Analyses
Data were analyzed using descriptive and inferential sta-
tistics with SPSS for Windows Version 18.0 (SPSS Inc.,
Chicago, IL) and GraphPad Prism (GraphPad Software,
Inc., La Jolla, CA) statistical programs. Data were evalu-
ated for normal distributions by evaluating for skewness
and kurtosis. Because synovial fluid biomarker concen-
trations were not normally distributed, Mann Whitney
U tests were used to determine if significant differences
existed between the median values of two groups. A
two-way analysis of variance was used to determine if
differences in anti-inflammatory medication use affected
biomarker results. The alpha level (p ≤ 0.05) was
adjusted with Bonferroni corrections for the 8 biomar-
ker comparisons (p ≤ 0.006).
Results
Participant characteristics
Osteoarthritis (OA) was confirmed in each group radio-
graphically; Kellgren-Lawrence scores are reported in
Table 1. The knees with effusion group consisted of 6
females and 5 males (mean age of 66.1 ± 9.4 years and
mean body mass index of 33.61 ± 6.40 kg/m
2; nine with
Kellgren-Lawrence scores of 3 and two with Kellgren-
Lawrence scores of 4). The knees without effusion
group consisted of 7 females and 4 males (mean age of
62.9 ± 5.3 years and mean body mass index of 34.26 ±
7.68 kg/m
2; nine with Kellgren-Lawrence scores of 3
and two with Kellgren-Lawrence scores of 4). Age and
body mass index were not significantly different between
the two groups. Three participants in the knees without
effusion group self-reported no history of knee swelling.
The remaining eight participants in the knees without
effusion group were currently having knee discomfort
and were not currently effused however, each reported a
history of knee swelling. The knees with effusion group
had 10 of 11 participants and the knees without effusion
group had 8 of 11 participants taking an anti-inflamma-
tory medicine for management of their OA symptoms
(Table 1).
Biochemical distinction of knees with and without
effusion
Median and confidence intervals for synovial fluid con-
centrations are presented in Table 2. The knees with
Table 1 Patient characteristics and medication use
Participant Gender KL Grade Age BMI NSAID Medication
Effusion group
1 Male 3 62 49.61 No None
2 Female 4 67 34.64 No Acetaminophen, calcium
3 Female 3 59 40.02 Yes Ibuprofen
4 Female 3 55 30.73 Yes Naproxen
5 Female 3 64 34.92 Yes Ibuprofen
6 Female 3 56 28.79 Yes Ibuprofen
7 Male 3 74 28.95 Yes Ibuprofen, Acetaminophen
8 Male 3 85 28.25 Yes Naproxen
9 Female 3 77 30.47 Yes Ibuprofen
10 Male 4 68 29.33 Yes Ibuprofen
11 Male 3 60 34.02 Yes Naproxen, Glucosamine
No effusion group
12 Female 3 65 36.07 No Acetaminophen
13 Male 3 69 35.05 No Acetaminophen, Calcium
14 Male 4 66 41.23 No Acetaminophen
15 Female 3 56 31.06 No Acetaminophen
16 Female 3 70 31.65 Yes Naproxen
17 Female 3 69 23.61 Yes Chondroitin, Ibuprofen
18 Male 3 64 33.54 Yes Ibuprofen
19 Male 3 59 29.11 Yes Ibuprofen
20 Female 3 59 39.14 Yes Naproxen
21 Female 4 57 50.95 Yes Ibuprofen
22 Female 3 58 25.46 Yes Acetaminophen, Ibuprofen
Note: KL = Kellgren Lawrence, BMI = Body Mass Index, NSAID = Nonsteroidal Anti-inflammatory Drug
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TIMP-1 (9913%), and TIMP-2 (1213%) median concen-
trations (protective biomarkers) than the knees without
effusion group. The knees with effusion group also had
significantly higher median MMP-3 concentrations
(62204%; catabolic biomarker) than the knees without
effusion group. No other synovial fluid biomarker con-
centrations were statistically different. No significant
interaction (p = 0.322) was found between anti-inflam-
matory medication use and biomarker results when a
two-way analysis of variance was conducted.
Discussion
OA knees with effusion were biochemically distinct from
OA knees without effusion, providing support for the
hypothesis that effusion status may define an OA pheno-
type [11]. OA knees with effusion had elevated levels of
protective biomarkers (IL-10, TIMP-1, TIMP-2) and the
catabolic-associated biomarker MMP-3 compared to
knees without effusion. The current study is the first to
compare the biochemical profiles between OA knees with
and without effusion.
Three of the elevated biomarkers (TIMP-1, TIMP-2,
and MMP-3) in the OA knees with effusion group are
directly involved in the regulation of articular cartilage
extracellular matrix turnover [16,17]. MMP-3 is elevated
in nearly all diarthrodial joint OA tissues [18]. MMP-3
promotes proteoglycan breakdown and is expressed in a
stage-dependent manner: elevated higher in early-stage
OA than in late-stage OA [18]. TIMP-1 and TIMP-2,
inhibitors of MMPs, have also been reported to be ele-
vated in knee OA [16]. The increase in protective bio-
markers may represent a failing attempt to restore
homeostasis as the joint degenerates [19]. The current
study controlled for stage-dependent biochemical
changes by analyzing late-stage OA only (Kellgren-Lawr-
ence score ≥ 3). The findings of the current study suggest
that the OA knees with effusion had greater extracellular
matrix turnover than the knees without effusion group,
at least at the time of synovial fluid collection. The
detected changes are indicative of active cellular pro-
cesses at the time of fluid collection since eight of the ele-
ven participants in the knees without effusion group had
prior history of knee effusion and biomarkers have short
life spans. However, it remains unclear if the increased
extracellular matrix turnover caused the effusion or if the
presence of effusion lead to increased extracellular matrix
turnover. Future studies should focus longitudinally on
effusion status, biochemical changes, and the progression
of changes in function and structure to determine
causality.
Anabolic and protective activity increases when there is
structural damage to the articular cartilage (e.g., macro-
trauma, microtrauma) in an attempt to repair damaged
articular cartilage [20]. Collagen synthesis increases signifi-
cantly in late-stage OA but is insufficient to promote
recovery [21]. The elevated protective biomarkers (i.e., IL-
10, TIMP-1, TIMP-2), as well as the increase in MMP-3,
in the knees with effusion group may suggest that these
knees were in a more active degenerative state compared
to the knees without effusion group. In a limited sample of
knees (n = 20) with minimal baseline cartilage damage, the
presence of synovitis or effusion led to a trend for
increased odds of rapid cartilage loss [8,9]. The knees with
effusion group may represent a unique subset of OA but
more research is needed to further define the subset
Table 2 Synovial fluid biomarker concentrations (pg/μg of total protein) of osteoarthritic knees with and without
effusion
Non-Effused (n = 11) Effused (n = 11)
Biomarker Median (95% CI) Median (95% CI) p value r
IL-1b 0.000009
(0.000003 - 0.000023)
0.000012
(0.000006 - 0.000020)
0.714 -0.078
IL-10 0.000017
(0.000007 - 0.000039)
0.000054
(0.000037 - 0.000184)
0.003* -0.625
IL-13 0.000057
(0.000038 - 0.000173)
0.000047
(0.000034 - 0.000087)
0.670 -0.091
TIMP-1 0.519388
(0.000000 - 13.457844)
52.008696
(38.851239 - 80.618044)
< 0.001* -0.791
TIMP-2 0.340405
(0.000000 - 2.521999)
4.471101
(3.758427 - 5.662756)
0.002* -0.665
MMP-3 0.130385
(0.000000 - 6.931912)
81.236149
(0.000000 - 334.057639)
< 0.001* -0.819
OPG 0.000148
(0.000045 - 0.000281)
0.000104
(0.000116 - 0.000447)
0.224 -0.259
VEGF 0.001912
(0.000000 - 0.020470)
0.019389
(0.011830 - 0.033989)
0.013 -0.515
Note: CI = confidence interval, r = effect size, IL = interleukin, TIMP = tissue inhibitor of metalloproteinase, MMP = matrix metalloproteinase, OPG =
osteoprotegerin, and VEGF = vascular endothelial growth factor. * p ≤ 0.006 was considered significant.
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ally, further studies on biomarkers specific to collagen
turnover may help to validate that knees with effusion
may be an OA subset that are in a more active cartilage
degenerative state than knees without effusion.
Joint effusion is associated not only with cartilage turn-
over but also with synovitis. The use of imaging along
with biomarkers could help to determine the level of effu-
sion associated with synovitis. Synovitis is common in OA
and not just to the end stage of the disease process, as
some degree of synovitis is present in early OA as well
[22]. A total of 57% of knees with synovitis are associated
with elevated concentrations of the inflammatory biomar-
ker serum C-reactive protein [23]. The presence of synovi-
tis does not always result in an increase in inflammatory
mediators. The OA knee without effusion could also be
generating inflammatory mediators. Based on the current
study, it is likely that synovitis with elevated inflammation
does not vary between groups, although IL-10 was ele-
v a t e di nt h ek n e e sw i t he f f u s i o ng r o u pc o m p a r e dt ot h e
knees without effusion group. It is unclear which bio-
chemical mediators stimulate IL-10, as IL-10 is elevated in
OA joints and associated with chondroprotective as well
as anti-inflammatory roles. In the temporomandibular
joint, a biochemical comparison of joints with and without
effusion demonstrated significant differences in the con-
centrations of soluble cytokine receptors but IL-1 receptor
antagonist was not statistically different [24]. The implica-
tions to the knee are yet to be determined, as it is
unknown if differences exist between different synovial
joints.
In the current study, medication and supplement use
were controlled for by having patients self-report their
use and then analyzing if there were any significant bio-
chemical differences due to that use. Despite the disparity
in anti-inflammatory use between the two groups, none
of the inflammatory markers were statistically different
between groups. Accordingly, anti-inflammatory medica-
tion use had no overall effect on biomarker concentra-
tions. Patients may need to consume anti-inflammatory
medication regularly for the medications to influence
biomarker concentrations. It is plausible that anti-inflam-
matory medication use did not affect biomarker concen-
trations because they were not consumed consistently,
but the study questionnaires were not designed to con-
firm consistent medication use. Future research should
be conducted on patients using a broad range of inflam-
matory mediators and more detailed medication use data
to determine the extent that medication use effects bio-
chemical differences in knees with and without effusion.
The heterogeneity of OA is hindering progress in
developing new interventions and determining the effec-
tiveness of existing interventions for OA. The concept
of phenotyping subsets of OA patients has begun to
gain momentum [11,25,26], but which phenotypes are
clinically relevant remains unclear. More research is
needed to explore the biochemical differences between
an interaction of effusion status and symptoms (e.g.,
moderate-high symptoms with effusion, low symptoms
with effusion, low symptoms with non-effusion). This
may permit regression modeling to determine the asso-
ciation between clinical variables (e.g., quantification of
effusion, symptoms, and biochemical mediators) and the
development of individualized scores (continuous gradi-
ent model), taking one step forward in stratifying sub-
sets/phenotypes [11].
OA stratifications may be dependent on stable variables
(e.g., mechanism of onset, genetic risk factors, involved
joints), transient variables (e.g., effusion), or their interac-
tion. Effusion status is commonly conceptualized as a tran-
sient stratification; however, there may be a stable
stratification based on the history of knee effusion (e.g., no
history of knee effusion, history of knee effusion). In the
current study, three participants within the knees without
effusion group had no self-reported history of effusion.
These participants trended to having lower biomarker
concentrations than the other eight participants within the
knees without effusion group who self-reported a history
of effusion. The three participants with no self-reported
history of effusion were also three of the five knees with
the lowest concentrations of TIMP-1, TIMP-2, MMP-3,
and VEGF. Based on these findings, further research
should be conducted to determine if history of effusion
could possibly be used to determine stable stratifications
or phenotypes of OA. This may have implications when
assessing the effectiveness of interventions through clinical
trials. Each biochemical subset (stable or transient) may
respond differently to interventions. Future research
should focus on the effects of interventions on the bio-
chemical level in an effort to improve the overall clinical
care of OA.
This study was limited by the cross-sectional design and
the relatively small sample size. Future studies would be
strengthened by increasing the sample size, as well as
longitudinally following the patients. Furthermore, the
lack of imaging modalities (e.g., magnetic resonance ima-
ging, ultrasound) to objectively measure effusion and
synovitis levels limits the generalizability of the results.
Even with these limitations this study detected biochem-
ical differences between knees with and without effusion
that warrants further research.
Conclusions
The biochemical differences that existed between knees
with and without effusion provide preliminary data based
on a relatively small sample size to support that OA sub-
sets may exist, characterized by distinct biochemical
characteristics and clinical findings (e.g., effusion). These
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more attention in the future. Larger cohort studies
should be conducted to verifyt h i sf i n d i n g .P r e s u m a b l y ,
the biochemical distinction suggests that OA knees with
effusion may need to be managed differently than OA
knees without effusion.
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